A previous CASRAI guide, Patent Licensing: Exclusive Terms, Royalties, and Startup vs. Established Deals, explains the concepts behind a university patent license — exclusivity, field-of-use, royalty structures, diligence obligations. This page does something narrower and more concrete: it shows what those terms actually look like written into an agreement, with worked, illustrative numbers attached, so a research administrator who has never read a license before can recognize the shape of a real clause when one crosses their desk.
These are illustrative composite examples, not excerpts from any real, signed agreement. The clause language, dollar figures, and royalty rates below are constructed to show typical structure and typical ranges — drawn from widely published technology-transfer practice, not from any single institution’s actual deal terms. Every real license is negotiated individually; treat the numbers here as orientation, not as a benchmark to cite in a negotiation. For governing law and statutory background, see the Bayh-Dole Act dictionary entry and the patent-licensing guide linked above.
Example 1: An exclusive field-of-use license to a startup
This is the most common shape for a university license built around a single faculty invention with one identifiable commercial application.
Illustrative clause structure
- Grant clause: “Licensor grants Licensee an exclusive, worldwide license under the Licensed Patents to make, use, sell, and import Licensed Products solely within the Field of Use.”
- Field of Use: “the diagnosis and treatment of human oncological disease” — narrow enough that the university can license the same underlying patent separately for, say, veterinary or agricultural applications without conflict.
- Consideration: a $15,000 upfront license fee, reimbursement of the university’s accrued patent prosecution costs to date, a low-single-digit running royalty (illustrative: 2.5% of net sales), and 3% founder/company equity in lieu of a larger upfront cash payment — a common substitution when the licensee is a pre-revenue startup that cannot pay a large fee up front. See milestone payment for how staged payments are defined as a term of art.
- Diligence milestones: a schedule of dated commercialization checkpoints the licensee must hit to keep the exclusive grant — illustrative: IND-enabling studies complete within 24 months, first human dosing within 48 months, first commercial sale within 84 months. Missing a milestone typically triggers a cure period, then a right for the university to convert the license to non-exclusive or terminate it.
- Sublicensing: permitted with prior written university consent, with a defined split of any sublicense income (illustrative: 20% to the university on sublicense fees, separate from the running royalty on the licensee’s own sales).
Why each piece is there
The narrow field of use lets the university retain rights to license the same patent for unrelated applications — a single invention disclosure can sometimes support several licenses if the fields genuinely don’t overlap. Equity-in-lieu-of-fee is specific to startup deals; an established company licensee (see Example 2) is far more likely to pay meaningful cash upfront instead. The diligence-milestone structure exists because exclusivity is a public-interest bargain under Bayh-Dole: a university that grants exclusive rights to a federally funded invention and then lets the licensee sit on it indefinitely risks the invention never reaching the public, which is the harm the Act’s diligence and march-in provisions are meant to prevent.
Example 2: A non-exclusive license to an established company
Non-exclusive licenses are typically simpler and faster to negotiate because there’s no need to protect a single licensee’s exclusivity against future licensees.
Illustrative clause structure
- Grant clause: “Licensor grants Licensee a non-exclusive, non-transferable license…” — no field-of-use carve-out is usually needed, since the university remains free to license the same patent to others in parallel.
- Consideration: a larger upfront fee (illustrative: $75,000) reflecting the company’s established revenue base and lower execution risk, plus a running royalty in a comparable low-single-digit range, but typically no equity component — equity is a startup-specific substitute for cash, not a default term.
- No diligence-to-exclusivity milestones: because there’s no exclusivity to protect, non-exclusive agreements often drop the staged commercialization-milestone schedule entirely, replacing it with a simple annual minimum royalty or maintenance fee to keep the license in force.
- Reporting and audit rights: a clause requiring the licensee to deliver royalty reports on a fixed schedule (illustrative: quarterly, within 45 days of quarter-end) and giving the university the right to audit the licensee’s sales records, typically at the university’s expense unless an audit finds an underpayment above a stated threshold (illustrative: 5%), in which case the licensee bears the audit cost.
Example 3: A field-of-use split across two licensees
Sometimes a single patent covers a platform technology with genuinely separate commercial applications, and the university licenses it exclusively to two different companies in two different fields.
- Licensee A: exclusive field of use limited to “industrial water filtration applications.”
- Licensee B: exclusive field of use limited to “potable water treatment for municipal utilities.”
Each license is drafted with an explicit carve-out reserving the other field to the university, and often a mutual non-compete acknowledgment so neither licensee can later argue its exclusivity was implicitly broader than the stated field. Drafting the field-of-use boundary precisely is the single highest-stakes clause in this structure — an ambiguous boundary is a predictable source of later disputes between the two licensees, litigated through the university as the common licensor.
Example 4: A software/materials license with no patent underneath it
Not every license CASRAI’s audience encounters covers a patent. A university may also license copyrighted research software or a biological material where no patent claim exists (or the university chose not to pursue one).
- Grant clause covers copyright in the source code or tangible material transferred, not patent claims — the license is typically far narrower in scope (see material transfer agreement for the related, non-royalty-bearing instrument commonly used for research-only biological material transfers, and the guide on the MTA process).
- Software licenses to a for-profit user commonly include a restriction against reverse-engineering and a defined support/maintenance term, terms that have no equivalent in a patent license.
- Where the underlying work has open-source components, see Open Source Software Licensing in University Technology Transfer for how OSI-approved license terms (MIT, Apache 2.0, GPL) interact with a university’s own licensing terms.
Clauses that show up in nearly every license, regardless of type
Representations and warranties
The university typically warrants that it owns the IP and has the right to license it, but almost always disclaims any warranty that the licensed technology actually works, is free of third-party infringement claims, or is fit for a particular purpose — risk the licensee is expected to assess itself before signing.
Indemnification
The licensee commonly agrees to indemnify the university against product-liability claims arising from the licensee’s own commercialized product, since the university has no control over how the licensee ultimately manufactures, markets, or sells it.
Government rights reservation
For an invention made with federal funding, the license carries a reservation of the U.S. government’s royalty-free license to practice the invention and its retained march-in rights under Bayh-Dole — a clause that exists regardless of what the university and licensee separately negotiate.
Termination
Defines the events that end the license before its natural term — uncured breach, licensee bankruptcy, or (in an exclusive license) a diligence-milestone failure — and what happens to any sublicenses already granted when the head license terminates.
How to read an unfamiliar license quickly
- Find the grant clause first and confirm exclusive vs. non-exclusive and the field-of-use boundary — this single clause determines almost everything else about how the deal is priced and diligenced.
- Locate the consideration section and separate one-time payments (upfront fee, equity) from recurring ones (running royalty, minimum annual royalty, maintenance fee).
- Check whether diligence milestones exist and what happens on a miss — their presence usually signals an exclusive grant; their absence usually signals non-exclusive.
- Confirm the sublicensing terms and the associated revenue split, if the licensee is likely to sublicense downstream (common in pharma and platform-technology deals).
- Check for the federal-funding reservation clause if the underlying invention was federally funded — its absence in a license that should have one is a compliance gap worth flagging.
Frequently asked questions
Are these real license agreements?
No. Every clause and figure above is an illustrative composite constructed to show typical structure and typical ranges in published technology-transfer practice, not copied from any real, signed agreement. Real royalty rates, fees, and milestone schedules vary widely by field, invention stage, and negotiating leverage.
What’s a typical royalty rate in a university patent license?
Published surveys and practitioner guidance generally describe university patent license royalties clustering in the low-to-mid single digits of net sales, with the exact rate depending heavily on field, how far the invention has been developed, and competitive alternatives — see the range discussion in the CASRAI patent-licensing guide linked above rather than treating any single figure as standard.
Why do startup licenses take equity instead of a large upfront fee?
A pre-revenue startup usually cannot pay a meaningful upfront cash fee without diverting scarce early capital away from actually developing the technology. Equity lets the university share in the company’s eventual success without requiring cash the startup doesn’t yet have.
What happens if a licensee misses a diligence milestone?
Most exclusive licenses define a cure period after a missed milestone, followed by a defined remedy if the miss isn’t cured — commonly conversion of the license from exclusive to non-exclusive, or outright termination, rather than an automatic penalty.
Where can I see the underlying legal framework these clauses respond to?
See the Bayh-Dole Act dictionary entry, the Patent Licensing guide’s federally-funded-inventions section, and iEdison: Invention Reporting and Utilization Reports for the reporting side of a federally funded license.
